Currently, the company is developing a universal method for producing peptide hormones of the insulin superfamily.

The insulin superfamily is a large group of peptides with diverse physiological activities found throughout the animal kingdom. These peptides have a conserved structure and exhibit a wide range of biological activities, including glucose homeostasis, tissue growth, cardiovascular and reproductive processes, and others yet to be determined. To determine biological activity, a source of sufficient quantities of these peptides is necessary. Therefore, obtaining these peptides by chemical synthesis is a demanded task.

The history of the chemical synthesis of insulin, relaxins, and insulin-like peptides goes back to around 60 years. Over 40 years ago, the solid-phase method was introduced, along with new reagents and protecting groups. This expansion significantly increased the possibilities for synthesis  this family of peptides.

Based on these advancements, we have developed an efficient scheme for the synthesis of insulin-like peptides. Our approach allows us to obtain natural insulin-like peptides and their analogs, including challenging ones for chemical synthesis such as insulin-like peptide 5 (see pictures below).

The stability of our synthesis scheme allows us to reliably obtain multiple analogues of insulin-like peptides in small quantities (1-5 mg) sufficient for “screening research needs”. At the same time, when required, our lab production capacity allows us to scale up to 10g of individual peptide with a purity greater than 98% by HPLC.

You can find up-to-date information on our LinkedIn. We hope that our capabilities in the synthesis of insulin-like peptides will be of interest to a wide range of researchers and pharmaceutical companies.